Jonathan Corren

List of Publications by Year
in descending order

46 papers	3,166 citations	279487 23 h-index	253896 43 g-index
46 all docs	46 docs citations	46 times ranked	2847 citing authors

#	Article	IF	Citations
1	Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study. Journal of Allergy and Clinical Immunology, 2022, 149, 957-965.e3.	1.5	58
2	Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. Lancet Respiratory Medicine,the, 2022, 10, 47-58.	5.2	74
3	Bronchodilator Responsiveness: An Underappreciated Biomarker for Asthma Exacerbations. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 229-230.	2.0	0
4	Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps: Association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUSâ€24 and SINUSâ€52 trials. International Forum of Allergy and Rhinology, 2022, 12, 1191-1195.	1.5	9
5	Controversies in Allergy: Choosing a Biologic for Patients with Severe Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 410-419.	2.0	21
6	Baseline type 2 biomarker levels and response to tezepelumab in severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1786-1796.	2.7	49
7	EAACI Biologicals Guidelinesâ€"Recommendations for severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 14-44.	2.7	156
8	Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY. Annals of Allergy, Asthma and Immunology, 2021, 126, 187-193.	0.5	32
9	Dupilumab is effective in type 2â€high asthma patients receiving highâ€dose inhaled corticosteroids at baseline. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 269-280.	2.7	25
10	Reply. Journal of Allergy and Clinical Immunology, 2021, 147, 413-414.	1.5	2
11	Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study. Journal of Asthma and Allergy, 2021, Volume 14, 1-11.	1.5	21
12	Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma with and without Nasal Polyposis: A Post Hoc Analysis of the Phase 2b PATHWAY Study. Journal of Asthma and Allergy, 2021, Volume 14, 91-99.	1.5	34
13	Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1212-1223.e6.	2.0	31
14	A Comprehensive Analysis of the Stability of Blood Eosinophil Levels. Annals of the American Thoracic Society, 2021, 18, 1978-1987.	1.5	19
15	Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma. European Respiratory Journal, 2021, 58, 2004498.	3.1	9
16	Short-Term Subcutaneous Allergy Immunotherapy and Dupilumab are Well Tolerated in Allergic Rhinitis: A Randomized Trial. Journal of Asthma and Allergy, 2021, Volume 14, 1045-1063.	1.5	25
17	Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma and Perennial Allergy. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4334-4342.e6.	2.0	23
18	Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma. American Journal of Clinical Dermatology, 2021, 22, 101-115.	3.3	32

#	Article	IF	Citations
19	A real-world study of ICS use in patients with severe eosinophilic asthma treated with mepolizumab. Annals of Allergy, Asthma and Immunology, 2021, , .	0.5	2
20	Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 527-539.e9.	2.0	45
21	Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 516-526.	2.0	123
22	Biomarkers of Type 2 Airway Inflammation in Airway Disease: And Then There Were Two. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2640-2642.	2.0	4
23	COVID-19, asthma, and biological therapies: What we need to know. World Allergy Organization Journal, 2020, 13, 100126.	1.6	90
24	The effect of tezepelumab on hospitalizations and emergency department visits in patients with severe asthma. Annals of Allergy, Asthma and Immunology, 2020, 125, 211-214.	0.5	12
25	Reply. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 822.	2.0	0
26	Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. Journal of Allergy and Clinical Immunology, 2020, 146, 595-605.	1.5	380
27	Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelinesâ€"Recommendations on the use of biologicals in severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1058-1068.	2.7	67
28	Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab) Tj ETQq0 0 0 rgBT /Overlock 10 recommendations on the use of biologicals in severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1023-1042.	2.7	232
29	Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines â€•recommendations on the use of biologicals in severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1043-1057.	2.7	85
30	Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma. ERJ Open Research, 2020, 6, 00204-2019.	1.1	36
31	Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function . Journal of Asthma and Allergy, 2020, Volume 13, 701-711.	1.5	14
32	Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma. Annals of Allergy, Asthma and Immunology, 2019, 122, 41-49.e2.	0.5	50
33	New Targeted Therapies for Uncontrolled Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1394-1403.	2.0	59
34	Dupilumab improves asthma outcomes irrespective of frequency of previous asthma exacerbation history. Annals of Allergy, Asthma and Immunology, 2019, 123, 222-224.e1.	0.5	14
35	Advancing the Care of Severe Asthma: Differential Diagnosis, Multidisciplinary Management, and Patient Engagement. American Journal of Medicine, 2019, , .	0.6	2
36	Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial. ERJ Open Research, 2019, 5, 00009-2019.	1.1	36

#	Article	IF	Citations
37	TSLP: from allergy to cancer. Nature Immunology, 2019, 20, 1603-1609.	7.0	132
38	Patient-reported outcomes in moderate-to-severe allergic asthmatics treated with omalizumab: a systematic literature review of randomized controlled trials. Current Medical Research and Opinion, 2018, 34, 65-80.	0.9	7
39	Asthma Yardstick. Annals of Allergy, Asthma and Immunology, 2017, 118, 133-142.e3.	0.5	26
40	Inflammatory Disorders Associated with Allergy. Immunology and Allergy Clinics of North America, 2017, 37, 233-246.	0.7	3
41	Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma. Chest, 2016, 150, 799-810.	0.4	337
42	Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting Î²2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet, The, 2016, 388, 31-44.	6.3	760
43	Burden of Persistent Asthma in Patients Treated With Medium- to High-Dose Inhaled Corticosteroids: Baseline Data From a Phase 2 Clinical Trial of Dupilumab. Chest, 2015, 148, 4A.	0.4	2
44	Clinical utility and development of the fluticasone/formoterol combination formulation (Flutiform®) for the treatment of asthma. Drug Design, Development and Therapy, 2014, 8, 1555.	2.0	2
45	Evaluation and treatment of asthma: an overview. American Journal of Managed Care, 2005, 11, S408-15; quiz S427-33.	0.8	2
46	Optimum Treatment of Rhinitis in the Elderly. Drugs and Aging, 1995, 7, 168-175.	1.3	24